DNER and glioblastoma: However, although preclinical studies of various BET inhibitors have shown antitumor effects in glioblastoma models (reviewed in Yang et al20), clinical investigation has been limited, with a dose-finding study of OTX015 in patients with glioblastoma being discontinued due to lack of clinical activity after failing to meet its primary endpoint of 6-month PFS,21 suggestive of poor BBB penetration in humans and/or nonoptimal dosing.